DOLORES BRAY: Open Payments
NPI 1003852609 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,696 in 84 payments from 15 companies in 2025. Trend: 2023 $2,915 · 2024 $710 · 2025 $1,696
Food & beverage: $1,693Education: $4
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 15 | $511 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $328 |
| Neurocrine BioSciences, Inc. | 15 | $287 |
| Otsuka America Pharmaceutical, Inc. | 16 | $209 |
| E.R. Squibb & Sons, L.L.C. | 4 | $94 |
| Corium, LLC | 4 | $72 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| Novo Nordisk Inc | 1 | $31 |
| Neuronetics, Inc. | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $21 |
Products named: ARISTADA, CAPLYTA, INGREZZA, REXULTI, COBENFY, ABILIFY MAINTENA, Azstarys, FANAPT.
Industry payments across AL — which companies pay providers there.
